Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
22.91
-1.03 (-4.30%)
Oct 17, 2025, 6:05 PM CET
-4.30%
Market Cap9.25B
Revenue (ttm)2.62B
Net Income (ttm)-2.47B
Shares Outn/a
EPS (ttm)-6.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,807
Average Volume35,046
Open22.79
Previous Close23.94
Day's Range22.30 - 23.08
52-Week Range19.89 - 54.20
Betan/a
RSI52.76
Earnings DateNov 7, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

mRNA COVID shots may bolster effects of cancer treatments: study

mRNA-based COVID shots such as those from Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) could lift survival of cancer patients on immunotherapies. Read more here.

18 hours ago - Seeking Alpha

Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zone

The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the “Fear” zone on Monday. U.S. stocks settled higher on Monday, with the Dow Jones inde...

1 day ago - Benzinga

Monday Sector Leaders: Healthcare, Technology & Communications

Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.5%. Within that group, Moderna Inc (Symbol: MRNA) and Cooper Compani...

1 day ago - Nasdaq

Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News

Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News

1 day ago - GuruFocus

Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focus

U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher. On Sunday, President Donald Trump again warned that the U.S. economy would face significa...

2 days ago - Benzinga

Moderna (MRNA) Reveals Promising Data for Influenza Vaccines at IDWeek 2025

Moderna (MRNA) Reveals Promising Data for Influenza Vaccines at IDWeek 2025

2 days ago - GuruFocus

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe...

2 days ago - Wallstreet:Online

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, Octobe...

2 days ago - Accesswire

Moderna (MRNA) Reveals Promising Data from Cancer Study at ESMO 2025

Moderna (MRNA) Reveals Promising Data from Cancer Study at ESMO 2025

4 days ago - GuruFocus

Moderna (MRNA) Shares Decline After Reporting mRNA-4359 Results

Moderna (MRNA) Shares Decline After Reporting mRNA-4359 Results

4 days ago - GuruFocus

Moderna (MRNA) Shares Decline After Oncology Update

Moderna (MRNA) Shares Decline After Oncology Update

4 days ago - GuruFocus

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to r...

5 days ago - Wallstreet:Online

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to r...

5 days ago - Accesswire

Why Moderna Might Be a One-Hit Wonder

Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.

6 days ago - The Motley Fool

Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

7 days ago - Nasdaq

Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks

Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks

7 days ago - GuruFocus

Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment

Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment

8 days ago - GuruFocus

Moderna (MRNA) Tops Healthcare Short Interest Rankings

Moderna (MRNA) Tops Healthcare Short Interest Rankings

8 days ago - GuruFocus

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkp...

8 days ago - Benzinga

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna's Phase 1/2 study shows mRNA-4359 ... Full story available on Benzinga.com

8 days ago - Benzinga